Recurrent retroperitoneal lymphatic metastasis
Conditions
Interventions
Arm1:High-dose (145±15Gy) radioactive 125I seed implantation
Arm2:Low-dose (115±15Gy) radioactive 125I seed implantation
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients confirmed by pathology; 2. In patients with imaging evaluable lesions, the diameter was less than or equal to 7 cm; 3. The patients who have received external radiotherapy in the past can not tolerate or refuse to receive external radiotherapy again; 4. Patients who can tolerate anesthesia; 5. Patients who can tolerate puncture; 6. Patients aged 18-80 years old; 7. Patients with KPS >= 70; 8. Sufficient blood reserve: white blood cell count >= 3 x 10^9 / ml; granulocyte count >= 1.5 x 10^9 / ml; hemoglobin >= 90g / L; platelet > 50 x 10^9 / L; blood pressure >= 1.5 x 10^9 / ml; 9. Subjects with good liver function: serum total bilirubin concentration = 50%; 12. Patients whose expected survival time was more than 3 months; 13. Patients who volunteered and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients without proper puncture path; 2. Patients whose preoperative plan design can not meet the requirements of clinical treatment; 3. Patients with severe bleeding tendency, such as platelet 18S, prothrombin activity < 40%, and anticoagulant therapy and / or antiplatelet coagulation drugs stopped for less than 1 week before particle implantation; 4. Patients with severe complications leading to clinical risk (such as severe hypertension, diabetes, etc.); 5. Patients with skin ulceration caused by tumor; 6. Patients with active infectious diseases, trauma, stroke and severe trauma; 7. Patients with mental disorders; 8. Pregnant or lactating women; 9. Patients allergic to iodine contrast agent; 10. Patients participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dosimetry;Objective response rate;Disease control rate;Pain relief rate;Treatment-related toxicity;Overall survival;Quality of life; | — |
Countries
China
Contacts
Public ContactWang Junjie
Peking University Third Hospital
Outcome results
None listed